Skip to main content Help with accessibility Skip to main navigation

Dupilumab

Red

Brand:

Dupixent®

Nice TA:

534

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Skin

Background

Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if:
  • the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated
  • the company provides dupilumab according to the commercial arrangement.
    Stop dupilumab at 16 weeks if the atopic dermatitis has not responded adequately. An adequate response is:
  • at least a 50% reduction in the Eczema Area and Severity Index score (EASI 50) from when treatment started and
  • at least a 4‑point reduction in the Dermatology Life Quality Index (DLQI) from when treatment started

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 01 - Sep - 2018